We are live on ! Find out more
NYMX

Nymox Pharmaceutical Corp

Delisted

NYMX was delisted on the 6th of July, 2023.

45 hedge funds and large institutions have $17.1M invested in Nymox Pharmaceutical Corp in 2017 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 6

172% more capital invested

Capital invested by funds: $6.29M → $17.1M (+$10.8M)

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

55% more funds holding

Funds holding: 2945 (+16)

80% less call options, than puts

Call options by funds: $842K | Put options by funds: $4.16M

Holders
45
Holders Change
+16
Holders Change %
+55.17%
% of All Funds
1.12%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
22
Increased
8
Reduced
4
Closed
6
Calls
$842K
Puts
$4.16M
Net Calls
-$3.32M
Net Calls Change
-$150K
Name Holding Trade Value Shares
Change
Change in
Stake
Walleye Trading
51
Walleye Trading
New York
-$13 -3,600 Closed

NYMX Hedge Fund Activity: Q2 2017 in Review

45 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q2 2017, worth a combined $17.1M — up 172% from $6.29M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new NYMX positions and 6 closed out — a net gain of 16 holders — while 8 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $4.8M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $851K sold.

  • 45 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q2 2017, up from 29 in Q1 2017.
  • Funds reported $17.1M of Nymox Pharmaceutical Corp stock for Q2 2017, up 172% quarter-over-quarter.
  • 22 funds opened new Nymox Pharmaceutical Corp positions in Q2 2017 and 6 closed out, a net change of +16 holders.
  • The largest Nymox Pharmaceutical Corp buyer in Q2 2017 was BlackRock, an estimated $4.8M added.
  • The largest Nymox Pharmaceutical Corp seller in Q2 2017 was Susquehanna International Group, an estimated $851K sold.

Based on aggregated 13F filings for Q2 2017.